KTRA
Income statement / Annual
Last year (2024), Kintara Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Kintara Therapeutics, Inc.'s net income was -$8.50 M.
See Kintara Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$55,000.00 |
$60,000.00 |
$60,000.00 |
$32,000.00 |
$10,000.00 |
$16,348.00 |
$24,528.00 |
$16,683.00 |
$10,288.00 |
$0.00 |
| Gross Profit |
-$55,000.00 |
-$60,000.00 |
-$60,000.00 |
-$32,000.00 |
-$10,000.00 |
-$16,348.00 |
-$24,528.00 |
-$16,683.00 |
-$10,288.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$2.66 M
|
$9.31 M
|
$15.17 M
|
$11.82 M
|
$3.63 M
|
$3.66 M
|
$7.13 M
|
$5.00 M
|
$3.36 M
|
$2.56 M
|
| General & Administrative
Expenses |
$5.79 M
|
$5.49 M
|
$7.51 M
|
$9.76 M
|
$4.51 M
|
$4.74 M
|
$4.04 M
|
$3.32 M
|
$2.85 M
|
$2.17 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.79 M
|
$5.49 M
|
$7.51 M
|
$9.76 M
|
$4.51 M
|
$4.74 M
|
$4.04 M
|
$3.32 M
|
$2.85 M
|
$2.17 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$8.45 M |
$14.80 M |
$22.68 M |
$21.57 M |
$8.14 M |
$8.40 M |
$11.17 M |
$8.32 M |
$6.21 M |
$4.72 M |
| Cost And Expenses |
$8.45 M |
$14.80 M |
$22.68 M |
$21.57 M |
$8.14 M |
$8.40 M |
$11.17 M |
$8.32 M |
$6.21 M |
$4.72 M |
| Interest Income |
$0.00 |
$137,000.00 |
$14,000.00 |
$120.00 |
$75,248.00 |
$60,704.00 |
$33,243.00 |
$457.00 |
$108.00 |
$363.00 |
| Interest Expense |
$0.00 |
$0.00 |
$14,000.00 |
$26,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2,091.00 |
| Depreciation &
Amortization |
$55,000.00
|
$60,000.00
|
$60,000.00
|
$32,000.00
|
$10,000.00
|
$16,348.00
|
$24,528.00
|
$16,683.00
|
$10,288.00
|
$363.00
|
| EBITDA |
-$8.40 M
|
-$14.74 M
|
-$22.62 M
|
-$38.15 M
|
-$9.12 M
|
-$8.03 M
|
-$11.11 M
|
-$8.07 M
|
-$8.85 M
|
-$4.72 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$131,000.00
|
$147,000.00
|
$21,000.00
|
-$16.63 M
|
-$982,000.00
|
$350,275.00
|
$36,351.00
|
$324,159.00
|
-$2.27 M
|
$376,886.00
|
| Income Before Tax |
-$8.50 M |
-$14.65 M |
-$22.66 M |
-$38.30 M |
-$9.13 M |
-$8.05 M |
-$11.14 M |
-$8.08 M |
-$8.86 M |
-$4.80 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$76,000.00 |
-$147,000.00 |
-$42,000.00 |
$26,000.00 |
$981,372.00 |
-$639,846.00 |
-$39,459.00 |
-$477,673.00 |
$5.30 M |
$69,286.00 |
| Net Income |
-$8.50 M |
-$14.65 M |
-$22.62 M |
-$38.32 M |
-$10.11 M |
-$7.41 M |
-$11.14 M |
-$8.08 M |
-$8.86 M |
-$4.80 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-3.23 |
-9.04 |
-23.22 |
-74.02 |
-48.39 |
-143.87 |
-266.96 |
-335.43 |
-404.86 |
-251.98 |
| EPS Diluted |
-3.23 |
-8.62 |
-23.22 |
-74.02 |
-48.39 |
-143.87 |
-266.96 |
-335.43 |
-404.86 |
-251.98 |
| Weighted Average Shares
Out |
$2.64 M
|
$1.62 M
|
$974,000.00
|
$517,720.00
|
$208,880.00
|
$51,493.00
|
$41,722.00
|
$24,094.00
|
$21,896.00
|
$19,033.00
|
| Weighted Average Shares
Out Diluted |
$2.64 M
|
$1.70 M
|
$974,000.00
|
$517,720.00
|
$208,880.00
|
$51,493.00
|
$41,722.00
|
$24,094.00
|
$21,896.00
|
$19,033.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
